A method for treatment of HCV, comprising at least two direct-acting antiviral agents, ribavirin, but not interferon.

摘要

Use of at least two direct-acting antiviral agents (DAAs) and ribavirin for the preparation of compositions for combined or separate administration for the treatment of HCV in a patient infected with HCV genotype 1, wherein said at least two DAAs PSI-7977 and GS-5885, wherein said treatment does not include the administration of interferon and wherein said treatment lasts for 8, 9, 10, 11 or 12 weeks.